Symphony Financial Ltd. Co. Lowers Stock Holdings in Elevance Health, Inc. $ELV

Symphony Financial Ltd. Co. reduced its position in Elevance Health, Inc. (NYSE:ELV) by 71.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 763 shares of the company’s stock after selling 1,868 shares during the quarter. Symphony Financial Ltd. Co.’s holdings in Elevance Health were worth $245,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ELV. ARGA Investment Management LP purchased a new position in shares of Elevance Health during the 3rd quarter valued at $85,779,000. Mn Services Vermogensbeheer B.V. grew its position in Elevance Health by 1.2% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 85,600 shares of the company’s stock worth $27,659,000 after buying an additional 1,000 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in Elevance Health by 31.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 736 shares of the company’s stock worth $238,000 after acquiring an additional 177 shares during the last quarter. UniSuper Management Pty Ltd raised its holdings in shares of Elevance Health by 40.8% in the 3rd quarter. UniSuper Management Pty Ltd now owns 22,421 shares of the company’s stock valued at $7,245,000 after acquiring an additional 6,496 shares in the last quarter. Finally, Westfuller Advisors LLC purchased a new stake in shares of Elevance Health in the 3rd quarter valued at about $137,000. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ELV shares. Weiss Ratings upgraded shares of Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Robert W. Baird increased their target price on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Finally, Truist Financial set a $400.00 price target on Elevance Health in a research note on Tuesday, October 14th. Twelve investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $399.63.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $370.77 on Monday. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The stock has a market cap of $82.40 billion, a PE ratio of 15.16, a PEG ratio of 1.91 and a beta of 0.51. The company’s fifty day moving average is $349.17 and its 200 day moving average is $328.67. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.